ClinicalTrials.gg
RecruitingNCT06374719WiTNNessUpdated Jun 23, 2026

WiTNNess - TNNT1 Myopathy Natural History Study

An observational study in TNNT1-associated Myopathy, Infantile-onset Nemaline Rod Myopathy and Myopathies, Nemaline, sponsored by Clinic for Special Children. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Clinic for Special Children · Observational

How we know

From the registry’s dates

  • Started Sep 2018; still recruiting 8 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Muscular Diseases with a site in United States — 19 open to participants now, 27 under way, 5 of them phase 3. Muscular Diseases · United States.

Planned enrollment
21st of 30
40 · median 70
Started
2018
with 10 others
Observational
31 of 99
9 open now
Primary completion
2027-01
later than 4 of 25 live
Registered
84th of 99
by date

Among the 99 studies in Muscular Diseases with a site in United States, this one is the 21st largest by planned enrollment of the 30 observational ones that give a count, is one of 11 that started in 2018, is one of 31 observational ones, reaches primary completion later than 4 of the 25 other live ones, and was the 84th registered.

Muscular Diseases

232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.

Browse Muscular Diseases studies →

Open to participants now

19 of the 99 studies in Muscular Diseases with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Muscular Diseases with a site in United States, or all of them as a file.
02

Study summary

WiTNNess is designed to accurately document the natural course and variation of muscle disease caused by pathogenic changes of the TNNT1 gene. The primary aim of the study is to specify meaningful outcome measures for future clinical trials. WiTNNess is open to children and adults worldwide. Participants can choose to include their information once (cross-sectional cohort) or every few months (prospective cohort).

Read the detailed description

WiTNNess is an observational study that includes prospective and cross-sectional arms, both of which include people diagnosed with autosomal recessive TNNT1-associated muscle disease, commonly described as a form of infantile-onset (NEM5A) or childhood-onset (NEM5B) nemaline rod myopathy. The study's primary objective is to establish the nature and time course of disease outcomes under current treatment, so that these can later be compared to outcomes achieved with novel disease-modifying therapies (i.e., interventional trials).

Participants from all over the world are welcome to enroll in either arm of the WiTNNess study. Following appropriate consent, those in the prospective arm are followed long-term. Recurring assessments are performed at the participant's home, the Clinic for Special Children, or a partnering clinical site, depending on the individual's particular circumstances. Basic assessments include vital signs, a physical exam, documentation of motor milestones, growth measurements, and blood chemistry values. Participant's may also undergo non-invasive ultrasound of the heart (echocardiogram) and one or more chest radiographs.

Participants in the cross-sectional arm are contacted once after consent. Members of the WiTNNess study team partner with healthcare providers and family members to capture pertinent medical history, physical exam findings, growth metrics, and motor milestones at the time of contact.

03

Conditions studied

  • TNNT1-associated Myopathy
  • Infantile-onset Nemaline Rod Myopathy
  • Myopathies, Nemaline
  • Myopathy
  • Myopathy, Rod
  • Myopathy; Hereditary
  • Amish Nemaline Myopathy
  • Nemaline Myopathy 5
  • NEM5
  • Genetic Muscle Disease
  • Recessive Hereditary Disorder (Autosomal)
  • ANM

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes anyone diagnosed with biallelic pathogenic variants of TNNT1

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with biallelic pathogenic variants of TNNT1
  • Infantile-onset or childhood-onset proximal weakness without confounding medical conditions that could effect muscle health.

Exclusion criteria

Exclusion Criteria:

  • Another known or suspected medical condition (genetic or acquired) that could potentially alter the natural disease course or otherwise interfere with completion of study procedures.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Prospective

    Participants in the prospective cohort are enrolled during early infancy, shortly after diagnosis, and followed longitudinally with repeated assessments until reaching the primary study outcome.

  • Cross-Sectional

    Participants in the cross-sectional cohort enroll at any time after diagnosis and all study data are collected at a single time point.

06

What researchers measure

Primary outcomes

  1. Event-free survival

    The primary outcome is time until death or permanent ventilatory support, defined as any invasive (e.g., tracheostomy) or non-invasive (e.g., bilevel positive airway pressure) mechanical ventilatory assistance for ≥16 hours daily during ≥14 consecutive days in the absence of a reversible clinical state.

    Time frame: Day 1 up to 15 years

Secondary outcomes

  1. Motor Milestones

    Six motor milestones that include sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone, and walking alone, as defined by the Word Health Organization Multicentre Growth Reference Study.

    Time frame: All milestones normally achieved by postnatal age 17.1 months (normal 99th percentile reference value for independent walking).

  2. Thriving

    Maintain weight at ≥3rd WHO reference percentile for sex and age. The ability to swallow normally and maintain body weight equal to or greater than the WHO 3rd reference percentile for sex and age without requiring non-oral feeding support (i.e., nasogastric or gastrostomy tube).

    Time frame: Day 1 up to 15 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Jan 2027, 99 months after the start.

Of 36 observational studies under Muscular Diseases, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 159. This study's planned 99 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 19, 2024
StartActual
Sep 23, 2018
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06374719
Lead sponsor
Clinic for Special Children
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
Sep 23, 2018
Primary completion
Jan 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

Justin Hersh
Contact
jhersh@clinicforspecialchildren.org
7176879407
Joelle Williamson, MPH
Contact
jwilliamson@clinicforspecialchildren.org
7176879407
Vincent J Carson, MD
principal investigator · Clinic for Special Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion